clinical trial · NCT06653153
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Eli Lilly and Company·phase3·active not recruiting·n = 1,400
Alzheimer's DiseaseRemternetugPlacebo
brief summary
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.
started
Oct 24, 2024
primary completion
Apr 1, 2029
completion
Oct 1, 2030
last updated
Nov 20, 2025
official title
A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol